Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data
Background: Programmed cell death (PD)-1/PD-ligand 1 (PD-L1) inhibitors have made a breakthrough in the therapy of advanced urothelial bladder cancer (UBC). The impact of Fibroblast Growth Factor Receptor 3 (FGFR3) mutation on the effectiveness of PD-L1 treatment remains still unclear. Objective: Ou...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Pathology and Oncology Research |
| Subjects: | |
| Online Access: | https://www.por-journal.com/articles/10.3389/pore.2023.1611077/full |
| _version_ | 1797219159976706048 |
|---|---|
| author | Janos Revesz Boglarka Posfai Laszlo Pajor Timea Papdan Linda Varga Viktor R. Paczona Zoltan Varga Farkas Sukosd Aniko Maraz |
| author_facet | Janos Revesz Boglarka Posfai Laszlo Pajor Timea Papdan Linda Varga Viktor R. Paczona Zoltan Varga Farkas Sukosd Aniko Maraz |
| author_sort | Janos Revesz |
| collection | DOAJ |
| description | Background: Programmed cell death (PD)-1/PD-ligand 1 (PD-L1) inhibitors have made a breakthrough in the therapy of advanced urothelial bladder cancer (UBC). The impact of Fibroblast Growth Factor Receptor 3 (FGFR3) mutation on the effectiveness of PD-L1 treatment remains still unclear. Objective: Our study aimed to investigate the frequency of FGFR mutations at different tumor stages, and their relation to PD-L1 status and survival.Methods: 310 patients with urothelial bladder cancer and subsequent radical cystectomy were included in a retrospective study over a 10-year study period at the University of Szeged, Hungary. FGFR3 mutations from the most infiltrative areas of the tumor were analyzed by targeted next-generation sequencing and PD-L1 (28-8 DAKO) tests (tumor positive score -TPS and combined positives score–CPS). In T0 cases FGFR3 mutations were analyzed from the earlier resection samples. Survival and oncological treatment data were collected from the National Health Insurance Fund (NHIF). Neoadjuvant, adjuvant and palliative conventional chemotherapies were allowed; immunotherapies were not. The relationship between the covariates was tested using chi-square tests, and survival analysis was performed using the Kaplan-Meier model and Cox proportional hazards regression.Results: PD-L1 and FGFR could be tested successfully in 215 of the 310 UBC samples [pT0cyst 19 (8.8%); St.0-I 43 (20%); St.II 41 (19%); St.III-IV 112 (52%)]. Significant pairwise dependency was found between tumor stage, FGFR3 mutation status and PD-L1 expression (p < 0.01). Samples with FGFR mutation were more common in less advanced stages and were also less likely to demonstrate PD-L1 expression. The effect of all investigated factors on survival was found to correlate with tumor stage.Conclusion: FGFR alteration frequency varied between the different stages of cancer. Higher positivity rates were observed at early stages, but lower levels of PD-L1 expression were detected in patients with FGFR mutations across at all stages of the disease. |
| first_indexed | 2024-04-24T12:29:13Z |
| format | Article |
| id | doaj.art-0c6e848e2d6246fabbff4a99f75c4bf2 |
| institution | Directory Open Access Journal |
| issn | 1532-2807 |
| language | English |
| last_indexed | 2024-04-24T12:29:13Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Pathology and Oncology Research |
| spelling | doaj.art-0c6e848e2d6246fabbff4a99f75c4bf22024-04-08T07:33:38ZengFrontiers Media S.A.Pathology and Oncology Research1532-28072023-04-012910.3389/pore.2023.16110771611077Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world dataJanos Revesz0Boglarka Posfai1Laszlo Pajor2Timea Papdan3Linda Varga4Viktor R. Paczona5Zoltan Varga6Farkas Sukosd7Aniko Maraz8PhD School, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryDepartment of Urology, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryDepartment of Pathology, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryBackground: Programmed cell death (PD)-1/PD-ligand 1 (PD-L1) inhibitors have made a breakthrough in the therapy of advanced urothelial bladder cancer (UBC). The impact of Fibroblast Growth Factor Receptor 3 (FGFR3) mutation on the effectiveness of PD-L1 treatment remains still unclear. Objective: Our study aimed to investigate the frequency of FGFR mutations at different tumor stages, and their relation to PD-L1 status and survival.Methods: 310 patients with urothelial bladder cancer and subsequent radical cystectomy were included in a retrospective study over a 10-year study period at the University of Szeged, Hungary. FGFR3 mutations from the most infiltrative areas of the tumor were analyzed by targeted next-generation sequencing and PD-L1 (28-8 DAKO) tests (tumor positive score -TPS and combined positives score–CPS). In T0 cases FGFR3 mutations were analyzed from the earlier resection samples. Survival and oncological treatment data were collected from the National Health Insurance Fund (NHIF). Neoadjuvant, adjuvant and palliative conventional chemotherapies were allowed; immunotherapies were not. The relationship between the covariates was tested using chi-square tests, and survival analysis was performed using the Kaplan-Meier model and Cox proportional hazards regression.Results: PD-L1 and FGFR could be tested successfully in 215 of the 310 UBC samples [pT0cyst 19 (8.8%); St.0-I 43 (20%); St.II 41 (19%); St.III-IV 112 (52%)]. Significant pairwise dependency was found between tumor stage, FGFR3 mutation status and PD-L1 expression (p < 0.01). Samples with FGFR mutation were more common in less advanced stages and were also less likely to demonstrate PD-L1 expression. The effect of all investigated factors on survival was found to correlate with tumor stage.Conclusion: FGFR alteration frequency varied between the different stages of cancer. Higher positivity rates were observed at early stages, but lower levels of PD-L1 expression were detected in patients with FGFR mutations across at all stages of the disease.https://www.por-journal.com/articles/10.3389/pore.2023.1611077/fullurinary bladder cancerfibroblast growth factor receptorFGFR mutationprogrammed death-ligand 1 expressioncombined positive score |
| spellingShingle | Janos Revesz Boglarka Posfai Laszlo Pajor Timea Papdan Linda Varga Viktor R. Paczona Zoltan Varga Farkas Sukosd Aniko Maraz Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data Pathology and Oncology Research urinary bladder cancer fibroblast growth factor receptor FGFR mutation programmed death-ligand 1 expression combined positive score |
| title | Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data |
| title_full | Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data |
| title_fullStr | Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data |
| title_full_unstemmed | Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data |
| title_short | Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data |
| title_sort | correlation between fibroblast growth factor receptor mutation programmed death ligand 1 expression and survival in urinary bladder cancer based on real world data |
| topic | urinary bladder cancer fibroblast growth factor receptor FGFR mutation programmed death-ligand 1 expression combined positive score |
| url | https://www.por-journal.com/articles/10.3389/pore.2023.1611077/full |
| work_keys_str_mv | AT janosrevesz correlationbetweenfibroblastgrowthfactorreceptormutationprogrammeddeathligand1expressionandsurvivalinurinarybladdercancerbasedonrealworlddata AT boglarkaposfai correlationbetweenfibroblastgrowthfactorreceptormutationprogrammeddeathligand1expressionandsurvivalinurinarybladdercancerbasedonrealworlddata AT laszlopajor correlationbetweenfibroblastgrowthfactorreceptormutationprogrammeddeathligand1expressionandsurvivalinurinarybladdercancerbasedonrealworlddata AT timeapapdan correlationbetweenfibroblastgrowthfactorreceptormutationprogrammeddeathligand1expressionandsurvivalinurinarybladdercancerbasedonrealworlddata AT lindavarga correlationbetweenfibroblastgrowthfactorreceptormutationprogrammeddeathligand1expressionandsurvivalinurinarybladdercancerbasedonrealworlddata AT viktorrpaczona correlationbetweenfibroblastgrowthfactorreceptormutationprogrammeddeathligand1expressionandsurvivalinurinarybladdercancerbasedonrealworlddata AT zoltanvarga correlationbetweenfibroblastgrowthfactorreceptormutationprogrammeddeathligand1expressionandsurvivalinurinarybladdercancerbasedonrealworlddata AT farkassukosd correlationbetweenfibroblastgrowthfactorreceptormutationprogrammeddeathligand1expressionandsurvivalinurinarybladdercancerbasedonrealworlddata AT anikomaraz correlationbetweenfibroblastgrowthfactorreceptormutationprogrammeddeathligand1expressionandsurvivalinurinarybladdercancerbasedonrealworlddata |